Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.93
-0.05 (-0.63%)
At close: Sep 11, 2025, 4:00 PM EDT
7.95
+0.02 (0.25%)
After-hours: Sep 11, 2025, 4:00 PM EDT
Zevra Therapeutics Employees
Zevra Therapeutics had 59 employees as of December 31, 2024. The number of employees decreased by 10 or -14.49% compared to the previous year.
Employees
59
Change (1Y)
-10
Growth (1Y)
-14.49%
Revenue / Employee
$1,051,186
Profits / Employee
-$66,237
Market Cap
445.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59 | -10 | -14.49% |
| Dec 31, 2023 | 69 | 33 | 91.67% |
| Dec 31, 2022 | 36 | 12 | 50.00% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | 22 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZVRA News
- 7 days ago - Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire
- 14 days ago - Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire
- 16 days ago - Zevra Therapeutics to Participate at Upcoming Investor Conferences in September - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) - GlobeNewsWire